Long‐term weight outcomes in patients treated with liraglutide 3.0 mg in real‐world clinical practice

Abstract

SummaryLong‐term weight outcomes reflect the success of obesity treatment. Weight regain during treatment for obesity is a biologically maladaptive response that can be considered a central feature of the disease. This phenomenon has been well documented in patients treated with lifestyle changes and bariatric surgery. In patients treated with liraglutide 3.0 mg this has been documented in randomized control trials, but real‐world analysis is lacking. The aim of this retrospective observational study was to explore the long‐term weight outcomes in patients treated with liraglutide 3.0 mg in a real‐world clinical practice. The association between body composition changes and weight outcomes was also explored. The study included 25 patients treated with multi‐modal care that included liraglutide 3.0 mg over a period of 78 weeks. Body composition was examined via dual x‐ray absorptiometry at 16 and 32 weeks, with body weight captured up until 78 weeks for all patients. Weight loss (R2 = 0.39, p < .001), fat mass loss (R2 = 0.32, p = .003) and fat‐free mass loss (R2 = 0.19, p = .03) were all associated with weight change from artificial nadir, which was, on average, 3.8 kg. For body composition, after adjustment, only fat mass loss was associated weight regain (R2 = 0.32, p = .01). In conclusion, in patients with clinical obesity treated with liraglutide 3.0 mg in a real‐world clinical setting, fat mass loss was associated with weight regain. Whilst weight regain occurred on average, the magnitude was less than that observed in patients treated with lifestyle alone and weight loss remained clinically significant for most patients.